Overview

Exercise and Olanzapine-samidorphan

Status:
RECRUITING

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic exercise.

Phase:

PHASE4

Details

Lead Sponsor:

New York State Psychiatric Institute

Treatments:

Exercise